Disease · MONDO_0002025

psychiatric disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. psychiatric disorder. Diseases, record MONDO_0002025. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002025

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: psychiatric disorder; Open Targets
Open Targets ID: MONDO_0002025; Open Targets
Other names: Psychiatric disease; Open Targets
Disease Ontology: DOID:150; Disease Ontology
MeSH: D001523; MeSH
NCI Thesaurus: C2893; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 25 drugs, from TTD; Open Targets

Drugs25

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BECLAMIDE	CHEMBL64195	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PERICIAZINE	CHEMBL251940	Small molecule	Approval	TTD	1	0	0	Drugs and targets
BUPRENORPHINE	CHEMBL511142	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
PSILOCYBIN	CHEMBL194378	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
JNJ-40411813	CHEMBL3337527	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
OSORESNONTRINE	CHEMBL4206492	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
RALMITARONT	CHEMBL4594376	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
BIFIDOBACTERIUM SPP.	CHEMBL4297912		Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ILOPERIDONE	CHEMBL14376	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 25

See all 25 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	8	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	7	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 1	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor antagonist	Phase 1	https://conductscience.org/library/genes/3358	Drugs and targets
CHRNA1	Muscle-type nicotinic acetylcholine receptor	2	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1134	Drugs and targets
CHRNB1	Muscle-type nicotinic acetylcholine receptor	2	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1140	Drugs and targets
CHRND	Muscle-type nicotinic acetylcholine receptor	2	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1144	Drugs and targets
CHRNE	Muscle-type nicotinic acetylcholine receptor	2	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1145	Drugs and targets
CHRNG	Muscle-type nicotinic acetylcholine receptor	2	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1146	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01441960	Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)	Not applicable	45	2015-06-02	Neuromuscular Blockade, ECT	ROCURONIUM, SUXAMETHONIUM	Open Targets' reading of its record	ClinicalTrials.gov
NCT02087579	Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants	Phase 1	305		Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder	ARIPIPRAZOLE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT02066077	The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy	Not applicable	280		Major Depressive Disorder	ETOMIDATE, PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT01526395	Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital	Not applicable	99		Major Depressive Disorder, Bipolar Disorder, Schizophrenia	PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT07273851	Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy	Not applicable	80		Major Depressive Disorder	KETAMINE, PROPOFOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT06233344	Mindfulness-Assisted Psychedelic Therapy	Phase 2	40		Mental Health	PSILOCYBIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01495169	Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients	Phase 1	33		Safety and Tolerability of Iloperidone	ILOPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT06853171	Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders	Phase 1	24		Psychiatric Disorders	TROSPIUM CHLORIDE, XANOMELINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06332066	Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness	Phase 1	20		Mental Health Therapists	OXYTOCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01398189	F-18 Altanserin PET Study of Patients Receiving Clozapine	Not applicable	12		Schizophrenia, Schizoaffective Disorder	CLOZAPINE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
NMBA: Succinylcholine vs NMBA: Rocuronium: serious adverse events	0 of 45	0 of 45	90	NCT01441960

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002025

GET https://conductscience.org/api/diseases/v1/MONDO_0002025/drugs?page=2

API reference For AI assistants